Received: 24 September 2020
Accepted: 14 July 2021
First Online: 30 September 2021
: E.M.V.A. holds consulting roles with Tango Therapeutics, Genome Medical, Invitae, Enara Bio, Janssen, Manifold Bio, and Monte Rosa. E.M.V.A. has received research support from Novartis and BMS. E.M.V.A. owns equity in Tango Therapeutics, Genome Medical, Syapse, Enara Bio, Manifold Bio, Microsoft, and Monte Rosa and has received travel reimbursement from Roche–Genentech. E.M.V.A., B.R., and N.D.M. have institutional patents filed on methods for clinical interpretation (international application number PCT/US2019/027338). N.I.V. has served on the advisory board to Sanofi. The remaining authors declare no competing interests.